BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34524860)

  • 21. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.
    Garcia P; Harrod A; Jha S; Jenkins J; Barnhill A; Lee H; Thompson M; Williams JP; Barefield J; Mckinnon A; Suarez P; Shah A; Lowrey AJ; Bentz GL
    Antiviral Res; 2021 Apr; 188():105038. PubMed ID: 33577806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1.
    Brown JR; Conn KL; Wasson P; Charman M; Tong L; Grant K; McFarlane S; Boutell C
    J Virol; 2016 Jul; 90(13):5939-5952. PubMed ID: 27099310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic analysis of SUMO1-SUMOylome changes during defense elicitation in Arabidopsis.
    Ingole KD; Dahale SK; Bhattacharjee S
    J Proteomics; 2021 Feb; 232():104054. PubMed ID: 33238213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting SUMO Signaling to Wrestle Cancer.
    Kroonen JS; Vertegaal ACO
    Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models.
    Robillard L; Liao M; Nguyen M; Harding TC; Simmons AD; Dusek RL
    J Immunother; 2022 Oct; 45(8):335-348. PubMed ID: 35791438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small Ubiquitin-like Modifier Alters IFN Response.
    Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
    J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
    Demel UM; Böger M; Yousefian S; Grunert C; Zhang L; Hotz PW; Gottschlich A; Köse H; Isaakidis K; Vonficht D; Grünschläger F; Rohleder E; Wagner K; Dönig J; Igl V; Brzezicha B; Baumgartner F; Habringer S; Löber J; Chapuy B; Weidinger C; Kobold S; Haas S; Busse AB; Müller S; Wirth M; Schick M; Keller U
    J Clin Invest; 2022 May; 132(9):. PubMed ID: 35499080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
    Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
    Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Role for Protein Inhibitor of Activated STAT 4 (PIAS4) in the Restriction of Herpes Simplex Virus 1 by the Cellular Intrinsic Antiviral Immune Response.
    Conn KL; Wasson P; McFarlane S; Tong L; Brown JR; Grant KG; Domingues P; Boutell C
    J Virol; 2016 May; 90(9):4807-4826. PubMed ID: 26937035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Klebsiella pneumoniae Reduces SUMOylation To Limit Host Defense Responses.
    Sá-Pessoa J; Przybyszewska K; Vasconcelos FN; Dumigan A; Frank CG; Hobley L; Bengoechea JA
    mBio; 2020 Sep; 11(5):. PubMed ID: 32994335
    [No Abstract]   [Full Text] [Related]  

  • 36. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
    Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
    J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
    Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
    Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erratum to ‘‘Characterization of the regulatory roles of the SUMO.
    Hwang KW; Won TJ; Kim H; Chun HJ; Chun T; Park Y
    Diabetes Metab Res Rev; 2012 Feb; 28(2):196-202. PubMed ID: 22423385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diversification of SUMO-activating enzyme in Arabidopsis: implications in SUMO conjugation.
    Castaño-Miquel L; Seguí J; Manrique S; Teixeira I; Carretero-Paulet L; Atencio F; Lois LM
    Mol Plant; 2013 Sep; 6(5):1646-60. PubMed ID: 23482370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.